Lipocine Inc.

LPCNNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
2.05 USD
↘ 0.16 (7.24%)AT CLOSE (11:59 AM EDT)
2.07
↗ 0.02 (0.98%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
2.07
↗ 0.02 (0.98%)
🔴Market: CLOSED
Open?$2.20
High?$2.20
Low?$2.05
Prev. Close?$2.21
Volume?87.6K
Avg. Volume?108.7K
VWAP?$2.12
Rel. Volume?0.81x
Bid / Ask
Bid?$2.14 × 600
Ask?$2.25 × 100
Spread?$0.11
Midpoint?$2.20
Valuation & Ratios
Market Cap?16.9M
Shares Out?8.2M
Float?5.2M
Float %?93.4%
P/E Ratio?N/A
P/B Ratio?0.74
EPS?-$1.39
Dividend?0.00%
Ex-Dividend?N/A

LPCN is currently priced at $2.05. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place LPCN at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Themes
Biotech - Drug Development›Metabolic & Cardiometabolic
Employees
14
Market Cap
16.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.lipocine.com
Listed
2012-06-05
Address
675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, X1 84108
Phone: 801 994 7383
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
100
Piotroski F-Score?0/9Weak
Altman Z-Score?-8.20Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.97%Low
Short Interest?102.1K
Days to Cover?1.0
Free Float5.2M
Avg Daily Volume103.8K
Settlement Date2026-05-15
Financial Health
Current Ratio?9.99Strong
Quick Ratio?9.99Strong
Cash Ratio?1.98Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.74CHEAP▾
P/S?
Peers
100
S&P
10
8.98HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.0CHEAP▾
EV/Sales?
Peers
100
S&P
25
6.31HIGH▾
Returns & Efficiency
ROE?
S&P
3
-50.1%WEAK▾
ROA?
S&P
3
-45.1%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$11.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist